Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial (NCT04409834) | Clinical Trial Compass
CompletedPhase 4
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
United States390 participantsStarted 2020-08-05
Plain-language summary
The researchers wanted to learn how to help sick patients who are in the hospital because of COVID-19. They are trying to find out the best way that is safe to stop blood clots that could be dangerous from forming in patients with COVID-19. This research study happened at 34 hospitals.
All patients in the study took medicines that help prevent blood clots. These medicines are called blood thinners or anticoagulants. Patients got different amounts of blood thinners to see what works better and is safer. Researchers randomly chose some patients to get more and some to get less.
The researchers also wanted to know if another medicine called clopidogrel can safely help stop blood clots from forming. This kind of medicine helps keep parts of the blood, called platelets, from sticking together. In some patients who did not have other reasons to take a platelet-blocker the researchers randomly chose the patient to take clopidogrel or not. This type of medicine is also called an antiplatelet.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years (male or female)
✓. Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
✓. Currently admitted to an intensive care unit (ICU)
Exclusion criteria
✕. Ongoing (\>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication
✕. Ongoing or planned treatment with dual antiplatelet therapy
✕. Contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following:
✕. History of intracranial hemorrhage, known central nervous system (CNS) tumor or CNS vascular abnormality
✕. Active or recent major bleeding within the past 30 days with untreated source
✕. Platelet count \<70,000 or known functional platelet disorder
✕
What they're measuring
1
Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation
Timeframe: 28 days or until hospital discharge, whichever earlier
2
Venous or Arterial Thrombotic Events: Anti-platelet Therapy Versus No Anti-platelet Therapy
Timeframe: 28 days or until hospital discharge, whichever earlier